Oct. 22, 2021– Each October, national organizations aim to make more Americans aware of what they can do to prevent and treat breast cancer as well as support people whose lives have been affected by the disease. Breast Cancer Awareness Month also is a time to look at how the 340B drug pricing program can help expand prevention and treatment efforts. Screenings Are … [Read more...]
Federal Report Suggests Another Reason To End 340B Orphan Drug Loophole
Oct. 18, 2021– A new federal government report could add momentum to efforts on Capitol Hill to end limitations on 340B price discounts for orphan drugs purchased by certain safety-net hospitals. The report suggests that drug companies might be seeking orphan status for their products to maximize revenues and avoid paying 340B discounts on drugs widely used to treat common … [Read more...]
Seventh Drug Company Told It is Violating 340B Law
Oct. 12, 2021– Eight drug companies have restricted access to discounts to safety-net providers through the 340B drug pricing program on drugs dispensed at community-based pharmacies. Now the government officially has informed all but one of those companies that they are in violation of federal law and must restore the discounted pricing. The most recent recipient of a … [Read more...]
HHS Takes Vital Next Step Toward Ending 340B Pricing Denials
Oct. 1, 2021– The federal government has taken dramatic action to get drug companies to restore 340B pricing for outpatient prescription drugs dispensed by community pharmacies to patients of 340B hospitals. On Sept. 22, the Health Resources & Services Administration (HRSA) sent letters to six drugmakers informing them that the agency is asking the Office of Inspector … [Read more...]
Diabetes Care Bears the Brunt of Drugmakers’ 340B Restrictions
Sept. 23, 2021– The eight pharmaceutical companies that are restricting the discounts they offer through the 340B drug pricing program are blocking safety-net hospitals’ access to savings on a wide range of prescription drugs. But perhaps in no area is this more evident than when looking at the prices of diabetes drugs and the levels of lost 340B resources that otherwise would … [Read more...]
Report by Anti-340B Group Presents Erroneous Picture
Sept. 14, 2021– A new report issued by the Community Oncology Alliance (COA) claims 340B hospitals “charge both commercial payers and uninsured patients extraordinarily high prices and use an aggressive form of price discrimination between payers.” However, the report is highly flawed and presents an inaccurate picture of the role 340B plays in America’s health care safety … [Read more...]
Momentum Grows to End Medicare Cuts for 340B Hospitals
Sept. 9, 2021– Calls are increasing for the Biden administration to stop deep Medicare Part B payment cuts to many hospitals participating in the 340B drug pricing program. The reductions, which have been in place since January 2018, have been harmful for many safety-net hospitals and their patients. Earlier this summer, the administration issued proposed rules that would … [Read more...]